Morphoceuticals is a trailblazing, spinoff company from Tufts University whose intent is creating a basis for limb regeneration. Co-founders and lead scientists Dr. Michael Levin and Dr. David Kaplan have been able to induce full limb regeneration in a variety of animals, including frogs, that do not normally regenerate limbs. Dr. Levin and Dr. Kaplan's team are using many already FDA approved ion channel drugs via a "biodome" to administer long term limb growth. With a clear vision to revolutionize the field of regenerative medicine and restore lost limbs to those who have experienced limb loss, Morphoceuticals is at the forefront of limb regeneration research, bringing hope to patients in need. They are currently in pre-clinical trials with mammals and engaging the FDA on the necessary steps for clinical application regarding amputation stump health.
The Hartford Engineer a Limb (HEAL) Initiative is headed up by Dr. Cato Laurencin whose research has famously facilitated bone and knee ligaments growth. This program aims to combine many medical disciplines, such as stem cell science, to give limbs back to those who have lost them. Dr. Laurencin has set a goal of 2030 to complete this incredible mission.